Business
Nkarta to Present Preclinical Data from Engineered NK Cell Platform at the American Association for Cancer Research 2022 Annual Meeting
SOUTH SAN FRANCISCO, Calif., March 08, 2022 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing engineered natural killer
About this update from Nkarta, Inc.
[{"type":"text","content":"SOUTH SAN FRANCISCO, Calif., March 08, 2022 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing engineered natural killer (NK) cell therapies to treat cancer, today announced that it will present four posters at the upcoming American Association for Cancer Research (AACR) Annual Meeting to be held April 8 to 13, 2022. Abstracts are now available on the AACR website, www.aacr.org. Posters will be made available electronically on April 8, 2022 at 1:00 p.m. ET on the AACR e-poster website. Presented jointly with CRISPR Therapeutics: Title: CBLB, CISH and CD70 multiplexed gene knockout with CRISPR/Cas9 enhances cytotoxicity of CD70-CAR NK cells and provides greater resistance to TGF-β for cancer immunotherapySession Category: ImmunologySession Title: Preclinical ImmunotherapyAbstract Number: 5512 Nkarta presentations: Title: Surveying surface antigen expression in multiple myeloma preclinical modelsSession Category: Tumor BiologySession Title: Nonclinical Models of CancerAbstract Number: 6004 Title: Development of multiomics approaches to evaluate NKG2D ligand dynamics and anti-tumor immune responses during CAR-NK treatmentSession Category: Clinical Research Excluding TrialsSession Title: Immuno-oncologyAbstract Number: 5187 Title: Immune masking strategies to extend the pharmacokinetics of allogeneic cell therapiesSession Category: ImmunologySession Title: Preclinical ImmunotherapyAbstract Number: 5511 About NkartaNkarta is a clinical-stage biotechnology company advancing the development of allogeneic, off-the-shelf natural killer (NK) cell immunotherapies for cancer patients. By combining its cell expansion and cryopreservation platform with proprietary cell engineering technologies and CRISPR-based genome engineering capabilities, Nkarta is building a pipeline of future cell therapies engineered for deep anti-tumor activity and intended for broad access in the outpatient treatment setting. For more information, please visit the company’s website at www.nkartatx.com. Cautionary Note on Forward-Looking Statements Statements contained in this press release regarding matters that are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. Words such as \"anticipates,\" \"believes,\" \"expects,\" \"intends,\" “plan...